Cynata Company
The Cymerus technology utilises induced pluripotent stem cells (iPSC) and a recently identified precursor cell, known as a mesenchymoangioblast (MCA), to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale.
Technology:
RegMed
Industry:
Cell Therapy
Headquarters:
Armadale, Victoria, Australia
Founded Date:
2003
Employees Number:
1-10
Funding Status:
IPO
Register and Claim Ownership